Cardiol Therapeutics Inc.
CRDL•NASDAQ•Healthcare•Drug Manufacturers - Specialty & Generic

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyCAD - CAD
TypeStock
Share ClassClass A Shares

Contact Information

Websitewww.cardiolrx.com
Phone289 910 0850
Address
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5 Canada

Corporate Identifiers

CIK0001702123
CUSIP14161Y200
ISINCA14161Y2006
SIC2836

Leadership Team & Key Executives

David G. Elsley MBA
President, Chief Executive Officer and Director
Christopher J. Waddick C.A., C.M.A., CPA, MBA
Chief Financial Officer, Corporate Secretary and Director
Bernard Lim B.Sc.
Chief Operating Officer
Dr. Andrew Warwick Hamer M.D.
Chief Medical Officer and Head of Research and Development
Trevor Burns
Investor Relations
John A. Geddes BSCPT, MBA
Vice President of Corporate Development